

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., ACTAVIS
LABORATORIES FL, INC., AMNEAL PHARMACEUTICALS LLC,
AMNEAL PHARMACEUTICALS OF NEW YORK, LLC, DR. REDDY'S
LABORATORIES, INC., DR. REDDY'S LABORATORIES, LTD.,
SUN PHARMACEUTICALS INDUSTRIES, LTD.,
SUN PHARMACEUTICALS INDUSTRIES, INC.,
TEVA PHARMACEUTICALS USA, INC., WEST-WARD
PHARMACEUTICAL CORP., and HIKMA PHARMACEUTICALS, LLC,

Petitioners

v.

JANSSEN ONCOLOGY, INC.,

Patent Owner

Case IPR2016-01332¹

Patent 8,822,438 B2

DECLARATION OF IVAN T. HOFMANN, CPA/CFF, CLP

¹ Case IPR2017-00853 has been joined with this proceeding.

1. I, Ivan T. Hofmann, am over the age of eighteen (18) and otherwise competent to make this Declaration. I have personal knowledge of the facts set forth in this Declaration and am competent to testify to the same.


2. I have been retained by counsel for Petitioners in connection with the above-captioned *inter partes* review (“IPR”).

3. I am educated and experienced in economics, as detailed in my Declarations that were filed with the Petition and Reply as Exhibits MYL 1017 and MYL 1134, and my Curriculum Vitae filed as Attachment A-2 to MYL 1017 and MYL 1134. I understand that my declaration will be included in Petitioners’ Exhibit List as MYL Ex. 1151. I have examined Exhibit 1141. This exhibit is publicly available.

4. Exhibit MYL 1141 is a true and correct copy of a Johnson & Johnson press release entitled, “Zytiga[®] Approved In The EU For Use In The Treatment Of Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy,” dated January 11, 2013, accessible at <https://www.jnj.com/media-center/press-releases/zytiga-approved-in-the-eu-for-use-in-the-treatment-of-metastatic-castration-resistant-prostate-cancer-before-chemotherapy>. This Exhibit was downloaded at my direction and under my supervision. An exhibit label was added to this exhibit and no other alterations were made.

May 10, 2017

Respectfully submitted,



Ivan T. Hofmann, CPA/CFF, CLP